A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT06907615 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

243

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: HLX43 DOSE 1 (2.0 mg/kg)
DRUG: HLX43 DOSE 2 (2.5 mg/kg)

Sponsor

Shanghai Henlius Biotech

Collaborators

[object Object]